Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus

Expert Opinion on Therapeutic Targets

Volumn 20, Issue 9, 2016, Pages 1109-1125

  Song, Panai ^a,b,c   Onishi, Akira ^a,b,d   Koepsell, Hermann ^e   Vallon, Volker ^a,b,f  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d JICHI MEDICAL UNIVERSITY   (Japan)

^e UNIVERSITY OF WÜRZBURG   (Germany)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Diabetes mellitus; glucose transport; GSK 1614235; heart; hyperglycemia; intestine; kidney; LX4211; sodium glucose cotransporter

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; SODIUM GLUCOSE COTRANSPORTER 1; ANTIDIABETIC AGENT; SLC5A1 PROTEIN, HUMAN; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

DIABETES MELLITUS; DOWN REGULATION; GASTROINTESTINAL SYMPTOM; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE INTAKE; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; KIDNEY; KIDNEY PROXIMAL TUBULE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; SMALL INTESTINE; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; METABOLISM; MOLECULARLY TARGETED THERAPY;

ANIMALS; DIABETES MELLITUS; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; MOLECULAR TARGETED THERAPY; SODIUM-GLUCOSE TRANSPORTER 1; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84971635917     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2016.1168808     Document Type: Review

References (174)

1. K.Zierler Whole body glucose metabolism. Am J Physiol. 1999;276:E409–E426.
2. G.M.Kowalski, C.R.Bruce. The regulation of glucose metabolism:implications and considerations for the assessment of glucose homeostasis in rodents. Am J Physiol Endocrinol Metab. 2014;307:E859–E871.
3. M.Mueckler, B.Thorens. The SLC2 (GLUT) family of membrane transporters. Mol Aspects Med. 2013;34:121–138.
4. E.M.Wright, B.A.Hirayama, D.F.Loo. Active sugar transport in health and disease. J Intern Med. 2007;261:32–43.
5. E.M.Wright, D.D.Loo, B.A.Hirayama. Biology of human sodium glucose transporters. Physiol Rev. 2011;91:733–794.
6. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986.
7. V.Vallon. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med. 2015;66:255–270.
8. L.A.Gallo, E.M.Wright, V.Vallon. Probing SGLT2 as a therapeutic target for diabetes:basic physiology and consequences. Diab Vasc Dis Res. 2015;12:78–89.
9. A.J.Scheen. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75:33–59.
10. W.N.Washburn. Development of the renal glucose reabsorption inhibitors:a new mechanism for the pharmacotherapy of diabetes mellitus type 2. J Med Chem. 2009;52:1785–1794.
11. F.M.Hasan, M.Alsahli, J.E.Gerich. SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Res Clin Pract. 2014;104:297–322.
12. A.Novikov, V.Vallon. Sodium glucose cotransporter 2 inhibition in the diabetic kidney:an update. Curr Opin Nephrol Hypertens. 2016;25:50–58.
13. S.E.Inzucchi, B.Zinman, C.Wanner, et al. SGLT-2 inhibitors and cardiovascular risk:proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res. 2015;12:90–100.
14. B.Zinman, C.Wanner, J.M.Lachin, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
15. V.Gorboulev, A.Schurmann, V.Vallon, et al. Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes. 2012;61:187–196.• The study provides a description of the pivotal role of SGLT1 in intestinal glucose absorption and the glucose-induced secretion of GIP and GLP-1.
16. T.Rieg, T.Masuda, M.Gerasimova, et al. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Renal Physiol. 2014;306:F188–F193.• The study makes use of gene-targeted mouse models to show that SGLT2 and SGLT1 account for renal glucose reabsorption in euglycemia. When SGLT2 is fully inhibited, the increase in SGLT1-mediated glucose reabsorption explains why only 50–60% of filtered glucose is excreted.
17. V.Vallon, K.A.Platt, R.Cunard, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol. 2011;22:104–112.
18. D.R.Powell, C.M.DaCosta, J.Gay, et al. Improved glycemic control in mice lacking Sglt1 and Sglt2. Am J Physiol Endocrinol Metab. 2013;304:E117–E130.
19. U.M.Schmidt, B.Eddy, C.M.Fraser, et al. Isolation of (a subunit of) the Na+/D-glucose cotransporter(s) of rabbit intestinal brush border membranes using monoclonal antibodies. FEBS Lett. 1983;161:279–283.
20. B.E.Peerce, E.M.Wright. Conformational changes in the intestinal brush border sodium-glucose cotransporter labeled with fluorescein isothiocyanate. Proc Natl Acad Sci U S A. 1984;81:2223–2226.
21. M.A.Hediger, M.J.Coady, T.S.Ikeda, et al. Expression cloning and cDNA sequencing of the Na+/glucose co-transporter. Nature. 1987;330:379–381.
22. E.Turk, E.M.Wright. Membrane topology motifs in the SGLT cotransporter family. J Membr Biol. 1997;159:1–20.
23. N.K.Tyagi, A.Kumar, P.Goyal, et al. D-Glucose-recognition and phlorizin-binding sites in human sodium/D-glucose cotransporter 1 (hSGLT1):a tryptophan scanning study. Biochemistry. 2007;46:13616–13628.
24. M.A.Hediger, D.B.Rhoads. Molecular physiology of sodium-glucose cotransporters. Physiol Rev. 1994;74:993–1026.
25. C.S.Hummel, C.Lu, D.D.Loo, et al. Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2. Am J Physiol Cell Physiol. 2011;300:C14–C21.
26. J.Chen, S.Williams, S.Ho, et al. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther. 2010;1:57–92.
27. C.Bonner, J.Kerr-Conte, V.Gmyr, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21:512–517.
28. I.Vrhovac, E.D.Balen, D.Klessen, et al. Localizations of Na-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart. Pflugers Arch. 2015;467:1881–1898.• This study uses novel affinity-purified antibodies against human SGLT1 (hSGLT1) and SGLT2 (hSGLT2) to localize hSGLT2 in human kidney and hSGLT1 in human kidney, small intestine, liver, lung, and heart.
29. R.Poppe, U.Karbach, S.Gambaryan, et al. Expression of the Na+-D-glucose cotransporter SGLT1 in neurons. J Neurochem. 1997;69:84–94.
30. H.R.Kim, S.W.Park, H.J.Cho, et al. Comparative gene expression profiles of intestinal transporters in mice, rats and humans. Pharmacol Res. 2007;56:224–236.
31. A.I.Morrison, M.Panayotova-Heiermann, G.Feigl, et al. Sequence comparison of the sodium-D-glucose cotransport systems in rabbit renal and intestinal epithelia. Biochim Biophys Acta. 1991;1089:121–123.
32. Y.Kashiwagi, T.Nagoshi, T.Yoshino, et al. Expression of SGLT1 in human hearts and impairment of cardiac glucose uptake by phlorizin during ischemia-reperfusion injury in mice. PLoS One. 2015;10:e0130605.• The study provides evidence that SGLT1 may provide an important protective mechanism against schemia reperfusion injury by replenishing ATP stores in ischemic cardiac tissues via enhancing the availability of glucose, and provide new insights into the significant role of SGLTs in optimizing cardiac energy metabolism, at least during the acute phase of IRI.
33. M.J.Coady, A.M.Pajor, E.M.Wright. Sequence homologies among intestinal and renal Na+/glucose cotransporters. Am J Physiol. 1990;259:C605–C610.
34. L.Zhou, E.V.Cryan, M.R.D’Andrea, et al. Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1). J Cell Biochem. 2003;90:339–346.
35. S.K.Banerjee, K.R.McGaffin, N.M.Pastor-Soler, et al. SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states. Cardiovasc Res. 2009;84:111–118.
36. T.Yoshikawa, R.Inoue, M.Matsumoto, et al. Comparative expression of hexose transporters (SGLT1, GLUT1, GLUT2 and GLUT5) throughout the mouse gastrointestinal tract. Histochem Cell Biol. 2011;135:183–194.
37. V.Vallon, M.Gerasimova, M.A.Rose, et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol. 2014;306:F194–F204.
38. F.Gembardt, C.Bartaun, N.Jarzebska, et al. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension. Am J Physiol Renal Physiol. 2014;307:F317–F325.
39. N.M.Tabatabai, S.S.Blumenthal, D.L.Lewand, et al. Differential regulation of mouse kidney sodium-dependent transporters mRNA by cadmium. Toxicol Appl Pharmacol. 2001;177:163–173.
40. W.S.Lee, Y.Kanai, R.G.Wells, et al. The high affinity Na+/glucose cotransporter. Re-evaluation of function and distribution of expression. J Biol Chem. 1994;269:12032–12039.
41. D.Balen, M.Ljubojevic, D.Breljak, et al. Revised immunolocalization of the Na+-D-glucose cotransporter SGLT1 in rat organs with an improved antibody. Am J Physiol Cell Physiol. 2008;295:C475–C489.
42. K.Takata, T.Kasahara, M.Kasahara, et al. Immunohistochemical localization of Na(+)-dependent glucose transporter in rat jejunum. Cell Tissue Res. 1992;267:3–9.
43. W.Haase, K.Heitmann, W.Friese, et al. Characterization and histochemical localization of the rat intestinal Na(+)-D-glucose cotransporter by monoclonal antibodies. Eur J Cell Biol. 1990;52:297–309.
44. I.Sabolic, M.Skarica, V.Gorboulev, et al. Rat renal glucose transporter SGLT1 exhibits zonal distribution and androgen-dependent gender differences. Am J Physiol Renal Physiol. 2006;290:F913–F926.
45. H.Koepsell, K.Korn, A.Raszeja-Specht, et al. Monoclonal antibodies against the renal Na+-D-glucose cotransporter. Identification of antigenic polypeptides and demonstration of functional coupling of different Na+-cotransport systems. J Biol Chem. 1988;263:18419–18429.
46. K.Takata, T.Kasahara, M.Kasahara, et al. Localization of Na(+)-dependent active type and erythrocyte/HepG2-type glucose transporters in rat kidney:immunofluorescence and immunogold study. J Histochem Cytochem. 1991;39:287–298.
47. W.Haase, H.Koepsell. Electron microscopic immunohistochemical localization of components of Na+-cotransporters along the rat nephron. Eur J Cell Biol. 1989;48:360–374.
48. K.N.Lazaridis, L.Pham, B.Vroman, et al. Kinetic and molecular identification of sodium-dependent glucose transporter in normal rat cholangiocytes. Am J Physiol. 1997;272:G1168–G1174.
49. K.Mamchaoui, Y.Makhloufi, G.Saumon. Glucose transporter gene expression in freshly isolated and cultured rat pneumocytes. Acta Physiol Scand. 2002;175:19–24.
50. F.Bodega, C.Sironi, M.Armilli, et al. Evidence for Na+-glucose cotransporter in type I alveolar epithelium. Histochem Cell Biol. 2010;134:129–136.
51. X.Fan, O.Chan, Y.Ding, et al. Reduction in SGLT1 mRNA expression in the ventromedial hypothalamus improves the counterregulatory responses to hypoglycemia in recurrently hypoglycemic and diabetic rats. Diabetes. 2015;64:3564–3572.•• This study in hypoglycemic and diabetic rats indicated that inhibition of SGLT1 in the ventrolateral hypothalamus may diminish the risk of hypoglycemia in diabetes.
52. A.S.Yu, B.A.Hirayama, G.Timbol, et al. Functional expression of SGLTs in rat brain. Am J Physiol Cell Physiol. 2010;299:C1277–C1284.
53. A.S.Yu, B.A.Hirayama, G.Timbol, et al. Regional distribution of SGLT activity in rat brain in vivo. Am J Physiol Cell Physiol. 2013;304:C240–C247.
54. K.Elfeber, A.Kohler, M.Lutzenburg, et al. Localization of the Na+-D-glucose cotransporter SGLT1 in the blood-brain barrier. Histochem Cell Biol. 2004;121:201–207.
55. R.Sabino-Silva, H.S.Freitas, M.L.Lamers, et al. Na+-glucose cotransporter SGLT1 protein in salivary glands:potential involvement in the diabetes-induced decrease in salivary flow. J Membr Biol. 2009;228:63–69.
56. K.Elfeber, F.Stumpel, V.Gorboulev, et al. Na(+)-D-glucose cotransporter in muscle capillaries increases glucose permeability. Biochem Biophys Res Commun. 2004;314:301–305.
57. E.S.Hwang, B.A.Hirayama, E.M.Wright. Distribution of the SGLT1 Na+/glucose cotransporter and mRNA along the crypt-villus axis of rabbit small intestine. Biochem Biophys Res Commun. 1991;181:1208–1217.
58. B.A.Hirayama, H.C.Wong, C.D.Smith, et al. Intestinal and renal Na+/glucose cotransporters share common structures. Am J Physiol. 1991;261:C296–C304.
59. C.Sironi, F.Bodega, C.Porta, et al. Expression of Na+-glucose cotransporter (SGLT1) in visceral and parietal mesothelium of rabbit pleura. Respir Physiol Neurobiol. 2007;159:68–75.
60. E.S.Lein, M.J.Hawrylycz, N.Ao, et al. Genome-wide atlas of gene expression in the adult mouse brain. Nature. 2007;445:168–176.
61. R.B.Ervin, C.L.Ogden. Consumption of added sugars among U.S. adults, 2005–2010. NCHS data brief, no 122. Hyattsville (MD):National Center for Health Statistics; 2013.
62. K.Miyamoto, K.Hase, Y.Taketani, et al. Diabetes and glucose transporter gene expression in rat small intestine. Biochem Biophys Res Commun. 1991;181:1110–1117.
63. P.V.Roder, K.E.Geillinger, T.S.Zietek, et al. The role of SGLT1 and GLUT2 in intestinal glucose transport and sensing. PLoS One. 2014;9:e89977.
64. F.Gouyon, L.Caillaud, V.Carriere, et al. Simple-sugar meals target GLUT2 at enterocyte apical membranes to improve sugar absorption:a study in GLUT2-null mice. J Physiol. 2003;552:823–832.
65. V.Vallon, F.Grahammer, H.Volkl, et al. KCNQ1-dependent transport in renal and gastrointestinal epithelia. Proc Natl Acad Sci U S A. 2005;102:17864–17869.
66. M.G.Martin, E.Turk, M.P.Lostao, et al. Defects in Na+/glucose cotransporter (SGLT1) trafficking and function cause glucose-galactose malabsorption. Nat Genet. 1996;12:216–220.
67. E.Turk, B.Zabel, S.Mundlos, et al. Glucose/galactose malabsorption caused by a defect in the Na+/glucose cotransporter. Nature. 1991;350:354–356.
68. B.Zambrowicz, J.Freiman, P.M.Brown, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012;92:158–169.• This clinical study indicated that LX4211 can improve glycemic control in patients with type 2 diabetes without increasing gastrointestinal side effects. The data support further study of LX4211-mediated dual SGLT1/SGLT2 inhibition as a novel mechanism of action in the treatment of T2DM.
69. R.L.Dobbins, F.L.Greenway, L.Chen, et al. Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release. Am J Physiol Gastrointest Liver Physiol. 2015;308:G946–G954.•• The study uses the first selective SGLT1 inhibitors and shows that they inhibit intestinal glucose absorption in rats and humans. Moreover, they show that selective SGLT1 inhibition in humans enhances postprandial plasma GLP-1 levels.
70. F.M.Gribble. The gut endocrine system as a coordinator of postprandial nutrient homoeostasis. Proc Nutr Soc. 2012;71:456–462.
71. C.F.Deacon, B.Ahren. Physiology of incretins in health and disease. Rev Diabet Stud. 2011;8:293–306.
72. D.J.Drucker. Incretin action in the pancreas:potential promise, possible perils, and pathological pitfalls. Diabetes. 2013;62:3316–3323.
73. R.Moriya, T.Shirakura, J.Ito, et al. Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice. Am J Physiol Endocrinol Metab. 2009;297:E1358–E1365.
74. D.R.Powell, M.Smith, J.Greer, et al. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. J Pharmacol Exp Ther. 2013;345:250–259.• The study shows that LX4211, a dual sodium/glucose cotransporter 1 (SGLT1) and SGLT2 inhibitor, reduces intestinal glucose absorption and increases GLP-1 and PYY release, associated with a decrease in blood glucose excursions.
75. Z.Kokrashvili, B.Mosinger, R.F.Margolskee. T1r3 and alpha-gustducin in gut regulate secretion of glucagon-like peptide-1. Ann N Y Acad Sci. 2009;1170:91–94.
76. T.Shibazaki, M.Tomae, Y.Ishikawa-Takemura, et al. KGA-2727, a novel selective inhibitor of a high-affinity sodium glucose cotransporter (SGLT1), exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther. 2012;342:288–296.
77. G.Tolhurst, H.Heffron, Y.S.Lam, et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes. 2012;61:364–371.
78. A.Tavakkolizadeh, U.V.Berger, K.R.Shen, et al. Diurnal rhythmicity in intestinal SGLT-1 function, V(max), and mRNA expression topography. Am J Physiol Gastrointest Liver Physiol. 2001;280:G209–G215.
79. R.P.Ferraris, J.Diamond. Regulation of intestinal sugar transport. Physiol Rev. 1997;77:257–302.
80. J.Dyer, K.B.Hosie, S.P.Shirazi-Beechey. Nutrient regulation of human intestinal sugar transporter (SGLT1) expression. Gut. 1997;41:56–59.
81. D.B.Rhoads, D.H.Rosenbaum, H.Unsal, et al. Circadian periodicity of intestinal Na+/glucose cotransporter 1 mRNA levels is transcriptionally regulated. J Biol Chem. 1998;273:9510–9516.
82. A.Barfull, C.Garriga, A.Tauler, et al. Regulation of SGLT1 expression in response to Na(+) intake. Am J Physiol Regul Integr Comp Physiol. 2002;282:R738–R743.
83. J.Dyer, K.Daly, K.S.Salmon, et al. Intestinal glucose sensing and regulation of intestinal glucose absorption. Biochem Soc Trans. 2007;35:1191–1194.
84. R.F.Margolskee, J.Dyer, Z.Kokrashvili, et al. T1R3 and gustducin in gut sense sugars to regulate expression of Na+-glucose cotransporter 1. Proc Natl Acad Sci U S A. 2007;104:15075–15080.• This study shows that the sweet taste receptor subunit T1R3 and the taste G protein gustducin in enteroendocrine cells sense luminal glucose, which induces an upregulation of intestinal SGLT1 expression. This molecular pathway may provide novel therapeutic targets for modulating the gut’s capacity to absorb sugars.
85. M.Veyhl, T.Keller, V.Gorboulev, et al. RS1 (RSC1A1) regulates the exocytotic pathway of Na+-D-glucose cotransporter SGLT1. Am J Physiol Renal Physiol. 2006;291:F1213–F1223.
86. M.Veyhl, C.A.Wagner, V.Gorboulev, et al. Downregulation of the Na(+)- D-glucose cotransporter SGLT1 by protein RS1 (RSC1A1) is dependent on dynamin and protein kinase C. J Membr Biol. 2003;196:71–81.
87. M.Kroiss, M.Leyerer, V.Gorboulev, et al. Transporter regulator RS1 (RSC1A1) coats the trans-Golgi network and migrates into the nucleus. Am J Physiol Renal Physiol. 2006;291:F1201–F1212.
88. A.Vernaleken, M.Veyhl, V.Gorboulev, et al. Tripeptides of RS1 (RSC1A1) inhibit a monosaccharide-dependent exocytotic pathway of Na+-D-glucose cotransporter SGLT1 with high affinity. J Biol Chem. 2007;282:28501–28513.
89. M.Veyhl-Wichmann, A.Friedrich, A.Vernaleken, et al. Phosphorylation of RS1 (RSC1A1) steers inhibition of different exocytotic pathways for glucose transporter SGLT1 and nucleoside transporter CNT1, and an RS1-derived peptide inhibits glucose absorption. Mol Pharmacol. 2016;89:118–132.
90. G.L.Kellett, E.Brot-Laroche, O.J.Mace, et al. Sugar absorption in the intestine:the role of GLUT2. Annu Rev Nutr. 2008;28:35–54.
91. R.J.Naftalin. Does apical membrane GLUT2 have a role in intestinal glucose uptake? F1000Res. 2014;3:304.
92. R.M.Chaudhry, J.S.Scow, S.Madhavan, et al. Acute enterocyte adaptation to luminal glucose:a posttranslational mechanism for rapid apical recruitment of the transporter GLUT2. J Gastrointest Surg. 2012;16:312–319.
93. M.G.Martin, J.Wang, R.S.Solorzano-Vargas, et al. Regulation of the human Na(+)-glucose cotransporter gene, SGLT1, by HNF-1 and Sp1. Am J Physiol Gastrointest Liver Physiol. 2000;278:G591–G603.
94. S.Subramanian, P.Glitz, H.Kipp, et al. Protein kinase-A affects sorting and conformation of the sodium-dependent glucose co-transporter SGLT1. J Cell Biochem. 2009;106:444–452.
95. J.R.Hirsch, D.D.Loo, E.M.Wright. Regulation of Na+/glucose cotransporter expression by protein kinases in Xenopus laevis oocytes. J Biol Chem. 1996;271:14740–14746.
96. A.Ikari, H.Harada, K.Takagi. Role of actin in the cAMP-dependent activation of sodium/glucose cotransporter in renal epithelial cells. Biochim Biophys Acta. 2005;1711:20–24.
97. B.Elvira, S.Honisch, A.Almilaji, et al. Up-regulation of Na(+)-coupled glucose transporter SGLT1 by caveolin-1. Biochim Biophys Acta. 2013;1828:2394–2398.
98. M.Sopjani, S.K.Bhavsar, S.Fraser, et al. Regulation of Na+-coupled glucose carrier SGLT1 by AMP-activated protein kinase. Mol Membr Biol. 2010;27:137–144.
99. N.K.Gabler, J.S.Radcliffe, J.D.Spencer, et al. Feeding long-chain n-3 polyunsaturated fatty acids during gestation increases intestinal glucose absorption potentially via the acute activation of AMPK. J Nutr Biochem. 2009;20:17–25.
100. J.Walker, H.B.Jijon, H.Diaz, et al. 5-aminoimidazole-4-carboxamide riboside (AICAR) enhances GLUT2-dependent jejunal glucose transport:a possible role for AMPK. Biochem J. 2005;385:485–491.
101. M.Dieter, M.Palmada, J.Rajamanickam, et al. Regulation of glucose transporter SGLT1 by ubiquitin ligase Nedd4-2 and kinases SGK1, SGK3, and PKB. Obes Res. 2004;12:862–870.
102. M.Shojaiefard, N.Strutz-Seebohm, J.M.Tavare, et al. Regulation of the Na(+), glucose cotransporter by PIKfyve and the serum and glucocorticoid inducible kinase SGK1. Biochem Biophys Res Commun. 2007;359:843–847.
103. F.Grahammer, G.Henke, C.Sandu, et al. Intestinal function of gene-targeted mice lacking serum- and glucocorticoid-inducible kinase 1. Am J Physiol Gastrointest Liver Physiol. 2006;290:G1114–G1123.
104. F.Lang, K.Klingel, C.A.Wagner, et al. Deranged transcriptional regulation of cell-volume-sensitive kinase hSGK in diabetic nephropathy. Proc Natl Acad Sci U S A. 2000;97:8157–8162.
105. C.Sandu, R.Rexhepaj, F.Grahammer, et al. Decreased intestinal glucose transport in the sgk3-knockout mouse. Pflugers Arch. 2005;451:437–444.
106. S.Vayro, M.Silverman. PKC regulates turnover rate of rabbit intestinal Na+-glucose transporter expressed in COS-7 cells. Am J Physiol. 1999;276:C1053–C1060.
107. C.Castaneda-Sceppa, S.Subramanian, F.Castaneda. Protein kinase C mediated intracellular signaling pathways are involved in the regulation of sodium-dependent glucose co-transporter SGLT1 activity. J Cell Biochem. 2010;109:1109–1117.
108. C.Osswald, K.Baumgarten, F.Stumpel, et al. Mice without the regulator gene Rsc1A1 exhibit increased Na+-D-glucose cotransport in small intestine and develop obesity. Mol Cell Biol. 2005;25:78–87.
109. T.Korn, T.Kuhlkamp, C.Track, et al. The plasma membrane-associated protein RS1 decreases transcription of the transporter SGLT1 in confluent LLC-PK1 cells. J Biol Chem. 2001;276:45330–45340.
110. A.Filatova, M.Leyerer, V.Gorboulev, et al. Novel shuttling domain in a regulator (RSC1A1) of transporter SGLT1 steers cell cycle-dependent nuclear location. Traffic. 2009;10:1599–1618.
111. B.Elvira, M.Blecua, D.Luo, et al. SPAK-sensitive regulation of glucose transporter SGLT1. J Membr Biol. 2014;247:1191–1197.
112. S.S.Yarandi, G.Hebbar, C.G.Sauer, et al. Diverse roles of leptin in the gastrointestinal tract:modulation of motility, absorption, growth, and inflammation. Nutrition. 2011;27:269–275.
113. R.Ducroc, S.Guilmeau, K.Akasbi, et al. Luminal leptin induces rapid inhibition of active intestinal absorption of glucose mediated by sodium-glucose cotransporter 1. Diabetes. 2005;54:348–354.
114. H.Ogata, Y.Seino, N.Harada, et al. KATP channel as well as SGLT1 participates in GIP secretion in the diabetic state. J Endocrinol. 2014;222:191–200.
115. Y.Fujita, H.Kojima, H.Hidaka, et al. Increased intestinal glucose absorption and postprandial hyperglycaemia at the early step of glucose intolerance in Otsuka Long-Evans Tokushima Fatty rats. Diabetologia. 1998;41:1459–1466.
116. J.Dyer, I.S.Wood, A.Palejwala, et al. Expression of monosaccharide transporters in intestine of diabetic humans. Am J Physiol Gastrointest Liver Physiol. 2002;282:G241–G248.
117. D.K.Layman, P.Clifton, M.C.Gannon, et al. Protein in optimal health:heart disease and type 2 diabetes. Am J Clin Nutr. 2008;87:1571S–1575S.
118. S.Vestri, M.M.Okamoto, H.S.De Freitas, et al. Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat. J Membr Biol. 2001;182:105–112.
119. N.M.Tabatabai, M.Sharma, S.S.Blumenthal, et al. Enhanced expressions of sodium-glucose cotransporters in the kidneys of diabetic Zucker rats. Diabetes Res Clin Pract. 2009;83:e27–e30.
120. D.B.Vidotti, C.P.Arnoni, E.Maquigussa, et al. Effect of long-term type 1 diabetes on renal sodium and water transporters in rats. Am J Nephrol. 2008;28:107–114.
121. T.Adachi, K.Yasuda, Y.Okamoto, et al. T-1095, a renal Na+-glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats. Metabolism. 2000;49:990–995.
122. M.Kamran, R.G.Peterson, J.H.Dominguez. Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats. J Am Soc Nephrol. 1997;8:943–948.
123. J.H.Dominguez, K.Camp, L.Maianu, et al. Molecular adaptations of GLUT1 and GLUT2 in renal proximal tubules of diabetic rats. Am J Physiol. 1994;266:F283–F290.
124. J.J.Holst. Enteroendocrine secretion of gut hormones in diabetes, obesity and after bariatric surgery. Curr Opin Pharmacol. 2013;13:983–988.
125. L.J.Mandel. Metabolic substrates, cellular energy production, and the regulation of proximal tubular transport. Annu Rev Physiol. 1985;47:85–101.
126. V.Vallon, K.Sharma. Sodium-glucose transport:role in diabetes mellitus and potential clinical implications. Curr Opin Nephrol Hypertens. 2010;19:425–431.
127. V.Vallon, F.Grahammer, K.Richter, et al. Role of KCNE1-dependent K+ fluxes in mouse proximal tubule. J Am Soc Nephrol. 2001;12:2003–2011.
128. B.Komoroski, N.Vachharajani, D.Boulton, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther. 2009;85:520–526.
129. T.Heise, E.Seewaldt-Becker, S.Macha, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks’ treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15:613–621.
130. S.Sha, D.Devineni, A.Ghosh, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab. 2011;13:669–672.
131. D.R.Powell, C.M.DaCosta, M.Smith, et al. Effect of LX4211 on glucose homeostasis and body composition in preclinical models. J Pharmacol Exp Ther. 2014;350:232–242.• These preclinical studies show that LX4211 improves glycemic control and promotes weight loss by dual SGLT1/SGLT2 inhibition.
132. M.Brownlee. The pathobiology of diabetic complications:a unifying mechanism. Diabetes. 2005;54:1615–1625.
133. V.Vallon, S.C.Thomson. Renal function in diabetic disease models:the tubular system in the pathophysiology of the diabetic kidney. Annu Rev Physiol. 2012;74:351–375.
134. M.F.Albertoni Borghese, M.P.Majowicz, M.C.Ortiz, et al. Expression and activity of SGLT2 in diabetes induced by streptozotocin:relationship with the lipid environment. Nephron Physiol. 2009;112:45–52.
135. J.Marks, N.J.Carvou, E.S.Debnam, et al. Diabetes increases facilitative glucose uptake and GLUT2 expression at the rat proximal tubule brush border membrane. J Physiol. 2003;553:137–145.
136. A.K.Goestemeyer, J.Marks, S.K.Srai, et al. GLUT2 protein at the rat proximal tubule brush border membrane correlates with protein kinase C (PKC)-betal and plasma glucose concentration. Diabetologia. 2007;50:2209–2217.
137. C.Ghezzi, E.M.Wright. Regulation of the human Na+ dependent glucose cotransporter hSGLT2. Am J Physiol Cell Physiol. 2012;303:C348–C354.
138. F.Lang, C.Bohmer, M.Palmada, et al. (Patho)physiological significance of the serum- and glucocorticoid-inducible kinase isoforms. Physiol Rev. 2006;86:1151–1178.
139. T.F.Ackermann, K.M.Boini, H.Volkl, et al. SGK1-sensitive renal tubular glucose reabsorption in diabetes. Am J Physiol Renal Physiol. 2009;296:F859–F866.
140. H.J.Han, Y.J.Lee, S.H.Park, et al. High glucose-induced oxidative stress inhibits Na+/glucose cotransporter activity in renal proximal tubule cells. Am J Physiol Renal Physiol. 2005;288:F988–F996.
141. R.W.Schwenk, J.J.Luiken, A.Bonen, et al. Regulation of sarcolemmal glucose and fatty acid transporters in cardiac disease. Cardiovasc Res. 2008;79:249–258.
142. S.Boudina, E.D.Abel. Diabetic cardiomyopathy revisited. Circulation. 2007;115:3213–3223.
143. O.Asghar, A.Al-Sunni, K.Khavandi, et al. Diabetic cardiomyopathy. Clin Sci (Lond). 2009;116:741–760.
144. E.D.Abel, H.C.Kaulbach, R.Tian, et al. Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart. J Clin Invest. 1999;104:1703–1714.
145. W.T.Garvey, D.Hardin, M.Juhaszova, et al. Effects of diabetes on myocardial glucose transport system in rats:implications for diabetic cardiomyopathy. Am J Physiol. 1993;264:H837–H844.
146. D.D.Belke, T.S.Larsen, E.M.Gibbs, et al. Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice. Am J Physiol Endocrinol Metab. 2000;279:E1104–E1113.
147. R.Liao, M.Jain, L.Cui, et al. Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice. Circulation. 2002;106:2125–2131.
148. R.O.Pereira, A.R.Wende, C.Olsen, et al. GLUT1 deficiency in cardiomyocytes does not accelerate the transition from compensated hypertrophy to heart failure. J Mol Cell Cardiol. 2014;72:95–103.
149. R.O.Pereira, A.R.Wende, C.Olsen, et al. Inducible overexpression of GLUT1 prevents mitochondrial dysfunction and attenuates structural remodeling in pressure overload but does not prevent left ventricular dysfunction. J Am Heart Assoc. 2013;2:e000301.
150. Q.Liu, S.Wang, L.Cai. Diabetic cardiomyopathy and its mechanisms:role of oxidative stress and damage. J Diabetes Investig. 2014;5:623–634.
151. M.Balteau, N.Tajeddine, M.C.de, et al. NADPH oxidase activation by hyperglycaemia in cardiomyocytes is independent of glucose metabolism but requires SGLT1. Cardiovasc Res. 2011;92:237–246.
152. K.M.Mellor, U.Varma, D.I.Stapleton, et al. Cardiomyocyte glycophagy is regulated by insulin and exposure to high extracellular glucose. Am J Physiol Heart Circ Physiol. 2014;306:H1240–H1245.
153. J.Shearer, K.D.Ross, C.C.Hughey, et al. Exercise training does not correct abnormal cardiac glycogen accumulation in the db/db mouse model of type 2 diabetes. Am J Physiol Endocrinol Metab. 2011;301:E31–E39.
154. M.Ramratnam, R.K.Sharma, S.D’Auria, et al. Transgenic knockdown of cardiac sodium/glucose cotransporter 1 (SGLT1) attenuates PRKAG2 cardiomyopathy, whereas transgenic overexpression of cardiac SGLT1 causes pathologic hypertrophy and dysfunction in mice. J Am Heart Assoc. 2014;3(4). pii:e000899.
155. S.K.Banerjee, D.W.Wang, R.Alzamora, et al. SGLT1, a novel cardiac glucose transporter, mediates increased glucose uptake in PRKAG2 cardiomyopathy. J Mol Cell Cardiol. 2010;49:683–692.
156. C.Petersen. Analyse des Phloridzins. Annales Academie Science Francaise. 1835;15:178.
157. F.Castaneda, A.Burse, W.Boland, et al. Thioglycosides as inhibitors of hSGLT1 and hSGLT2:potential therapeutic agents for the control of hyperglycemia in diabetes. Int J Med Sci. 2007;4:131–139.
158. J.R.Ehrenkranz, N.G.Lewis, C.R.Kahn, et al. Phlorizin:a review. Diabetes Metab Res Rev. 2005;21:31–38.
159. A.T.Sands, B.P.Zambrowicz, J.Rosenstock, et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care. 2015;38:1181–1188.
160. N.C.Goodwin, R.Mabon, B.A.Harrison, et al. Novel L-xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes. J Med Chem. 2009;52:6201–6204.
161. D.R.Powell, M.G.Smith, D.D.Doree, et al. LP-925219 maximizes urinary glucose excretion in mice by inhibiting both renal SGLT1 and SGLT2. Pharmacol Res Perspect. 2015;3:e00129.
162. N.Fushimi, H.Teranishi, K.Shimizu, et al. Design, synthesis, and structure-activity relationships of a series of 4-benzyl-5-isopropyl-1H-pyrazol-3-yl β-D-glycopyranosides substituted with novel hydrophilic groups as highly potent inhibitors of sodium glucose co-transporter 1 (SGLT1). Bioorg Med Chem. 2013;21:748–765.
163. N.Fushimi, H.Fujikura, H.Shiohara, et al. Structure-activity relationship studies of 4-benzyl-1H-pyrazol-3-yl β-D-glucopyranoside derivatives as potent and selective sodium glucose co-transporter 1 (SGLT1) inhibitors with therapeutic activity on postprandial hyperglycemia. Bioorg Med Chem. 2012;20:6598–6612.
164. Q.Qiao, J.Tuomilehto, K.Borch-Johnsen. Post-challenge hyperglycaemia is associated with premature death and macrovascular complications. Diabetologia. 2003;46(Suppl 1):M17–M21.
165. J.H.O’Keefe, D.S.Bell. Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol. 2007;100:899–904.
166. C.Schulze, A.Bangert, G.Kottra, et al. Inhibition of the intestinal sodium-coupled glucose transporter 1 (SGLT1) by extracts and polyphenols from apple reduces postprandial blood glucose levels in mice and humans. Mol Nutr Food Res. 2014;58:1795–1808.
167. D.Polidori, S.Sha, S.Mudaliar, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion:results of a randomized, placebo-controlled study. Diabetes Care. 2013;36:2154–2161.
168. T.Oguma, K.Nakayama, C.Kuriyama, et al. Intestinal sodium glucose cotransporter 1 inhibition enhances glucagon-like peptide-1 secretion in normal and diabetic rodents. J Pharmacol Exp Ther. 2015;354:279–289.
169. L.Rossetti, D.Smith, G.I.Shulman, et al. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest. 1987;79:1510–1515.
170. E.M.Wright. I. Glucose galactose malabsorption. Am J Physiol. 1998;275:G879–G882.
171. P.R.Kiela, H.Xu, F.K.Ghishan. Apical NA+/H+ exchangers in the mammalian gastrointestinal tract. J Physiol Pharmacol. 2006;57(Suppl 7):51–79.
172. S.R.Joshi, E.Standl, N.Tong, et al. Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus:an evidence-based review. Expert Opin Pharmacother. 2015;16:1959–1981.
173. Q.Cai, B.Li, F.Yu, et al. Investigation of the protective effects of phlorizin on diabetic cardiomyopathy in db/db mice by quantitative proteomics. J Diabetes Res. 2013;2013:263845.• This paper reported that intragastrical administration of phlorizin can prevent the phenotype of diabetic cardiomyopathy, including hypertrophy and disarray of cardiomyocytes in T2DM db/db mice, through modulating cardiac lipid and energy metabolism and altering the expression of a set of proteins involved in cardiac damage.
174. F.M.Gribble, L.Williams, A.K.Simpson, et al. A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes. 2003;52:1147–1154.